retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide: A Promising Option for

Retatrutides effectiveness in both adipose tissue reduction and glycemic control suggests it could be a game-changing therapy for type 2 diabetes and obesity management (McPherson et al., 2023)

Find articles by Zanchi, D

No need to step through the lower doses again.It's a straightforward switch and for many, probably a welcome one.The MHRA's approval marks the first time a GLP-1 tablet of this kind has been cleared for use in the UK, and it signals a broader shift in how weight management treatment might look in the years ahead

Most do not find differences in sweet taste perception between individuals with and without obesity